PBE - PowerShares Dynamic Biotech & Genome ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
+0.36 (+0.70%)
At close: 3:31PM EDT
Stock chart is not supported by your current browser
Previous Close51.24
Bid0.00 x 0
Ask0.00 x 0
Day's Range51.34 - 51.75
52 Week Range40.77 - 54.28
Avg. Volume14,051
Net Assets249.91M
PE Ratio (TTM)N/A
YTD Return8.51%
Beta (3y)1.53
Expense Ratio (net)0.58%
Inception Date2005-06-23
Trade prices are not sourced from all markets
  • Exploring Ionis’s 3Q17 Quarterly Revenue Trend
    Market Realist2 months ago

    Exploring Ionis’s 3Q17 Quarterly Revenue Trend

    As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.

  • Harvest Exchange6 months ago

    Gene-Editing Could Modify and Cure Disease: CRISPR vs. TALENs

    The following is original research by ARK's Genomic Revolution Analyst, Manisha Samy . Genome-Editing During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in ...

  • A Shot in the Arm for the UK Life Sciences Industry?
    Harvest Exchange6 months ago

    A Shot in the Arm for the UK Life Sciences Industry?

    Prime Minister May Looks to Bolster the Sector Earlier this year, Prime Minister Theresa May earmarked life sciences as one of five areas critical to the UK’s economic growth and commissioned a proposal on how to bolster the sector, especially as the ...

  • Market Realist6 months ago

    How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?

    Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.

  • Market Realist7 months ago

    What’s Ionis Pharmaceuticals’ Valuation?

    Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

  • Market Realist8 months ago

    What Drove Biogen Stock in 2Q17?

    Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.

  • Market Realist9 months ago

    How Incyte’s Valuation Has Changed since 1Q17 Results

    Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

  • Market Realist9 months ago

    Changes in Ionis Pharmaceuticals’ Valuation after 1Q17

    In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we'll look at its ...